Glaxosmithkline Pharmaceuticals Ltd vs Procter Gamble Health Ltd Stock Comparison
Glaxosmithkline Pharmaceuticals Ltd vs Procter Gamble Health Ltd Stock Comparison
Last Updated on: May 05, 2026
Key Highlights
The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2362 as of 05 May 15:30
. The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Procter & Gamble Health Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Procter & Gamble Health Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Procter & Gamble Health Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Procter & Gamble Health Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80%
The net profit of Procter & Gamble Health Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The dividend payout of Glaxosmithkline Pharmaceuticals Ltd changed from 99.54 % to 92.72 % over 5 quarters. This represents a CAGR of -5.52%
The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00%
.
About Glaxosmithkline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001.
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.
About Procter & Gamble Health Ltd
Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations.
Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.
FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Procter & Gamble Health Ltd
Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Procter & Gamble Health Ltd?
Market cap of Glaxosmithkline Pharmaceuticals Ltd is 40,017 Cr while Market cap of Procter & Gamble Health Ltd is 8,566 Cr
What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Procter & Gamble Health Ltd?
The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Procter & Gamble Health Ltd?
As of May 5, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2362.25. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹5160.9.
How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Procter & Gamble Health Ltd compare?
To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.